Dermatological Drugs Market Size, Share & Trends Analysis Report By Therapy (Acne, Psoriasis, Rosacea), By Type, By Route Of Administration, By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Dermatological Drugs Market Size & Trends

The global dermatological drugs market size was valued at USD 23.9 billion in 2024 and is anticipated to grow at a CAGR of 10.1% from 2025 to 2030. Key factors driving the market include skin parasites, fungi, bacteria trapped in pores and hair follicles, fluid retention, dehydration prevention, and rising pollution levels. Increasing awareness of skin diseases, the demand for rapid diagnosis, and innovative treatments are further growing in the market. Moreover, significant investments in research and development lead to new medications, and the availability of over-the-counter products makes treatments more accessible, contributing to overall growth.

The increasing prevalence of skin conditions such as acne, psoriasis, and rosacea is increasing the demand for effective treatments such as topical retinoids, topical corticosteroids, and oral antibiotics. In addition, skin treatment includes laser therapy, topical & systemic medications, photodynamic therapy, radiotherapy, vitiligo surgery, and dermatological surgery. According to an article published by Healio in November 2024, Clindamycin is an effective treatment for acne vulgaris, available in topical and oral forms, as it helps reduce the risk of antibiotic resistance. The FDA has approved a new triple-combination gel with clindamycin, which has shown better results than other treatments.

Advancements in technology such as nanotechnology, enhanced drug formulations, and targeted therapies are strengthening the market growth due to the effectiveness of treatments. For instance, an article published by Pharmaceutical Technology stated that Almirall partnered with Microsoft to improve drug discovery and is expected to introduce new dermatology treatments with AI technology in February 2024. Furthermore, this helps to accelerate the discovery of effective treatments for skin diseases, demonstrating growth in the pharmaceutical industry toward integrating technology into drug development.

Standard protocols such as the selection of guidelines, selection of medications, monitoring, and follow-up are prioritized for dermatological drugs. For instance, the FDA approved a new drug, EBGLYSS, developed by Eli Lilly in September 2024. The drug is designed to treat severe atopic dermatitis, known as eczema. Clinical trials stated that 38.0% of the patients experienced clear skin after 16 weeks of treatment. Therefore, the treatment is effective for patients struggling with eczema and is driving growth in the market.

Therapy Insights

The psoriasis segment dominated the market with the largest revenue share of 50.6% in 2024, which can be attributed to the awareness of the disease and the demand for effective treatments. The increased awareness of psoriasis has contributed to the demand for effective diagnoses and treatments. Approval of new drugs by regulatory agencies also increases the options available to patients, while many prefer oral medications over injections. According to an article published by Business Wire in September 2024, Organon acquired Dermavant Sciences. This includes VTAMA (tapinarof) cream, a non-steroidal treatment approved for severe plaque psoriasis in adults. The treatment is effective for patients struggling with skin conditions.

The acne segment is expected to grow with a significant CAGR of 10.0% over the forecast period, attributed to the increasing prevalence of acne, especially among teenagers and young adults. According to a study by the National Institutes of Health, patients are seeking effective treatments, with about 80.0% of adolescents experiencing the condition. In addition, advancements in treatment options, such as new drug formulations and combination therapies, have improved efficacy in managing acne. Furthermore, there is also a growing awareness of skincare and the importance of addressing acne, influenced by social media and consumer interest in health and wellness. The accessibility of over-the-counter (OTC) acne medications allows more individuals to find solutions for their skin concerns without needing prescriptions, further supporting market growth.

Type Insights

The prescription segment dominated the market for the largest revenue share of 61.9% in 2024 and is expected to grow over the fastest CAGR of 10.4% over the forecast period. The segment growth can be attributed to the rising prevalence of skin diseases, such as psoriasis and eczema, which leads to patients seeking medical help and requiring treatment. In addition, advancements in drug development are resulting in innovative therapies, such as biologics and targeted treatments, offer better results. Furthermore, improved healthcare access and the availability of medications have made it easier for patients to receive treatments, contributing to the growth of prescriptions in the market.

The over-the-counter segment is projected to grow at a significant CAGR over the forecast period, due to the increasing awareness of skin conditions such as acne, eczema, and psoriasis, leading to higher demand for treatments. In addition, the convenience and affordability of OTC medications compared to prescription drugs make them a preferred choice for many consumers. The growth of e-commerce and online pharmacies also enhances accessibility, allowing patients to obtain these products easily. Therefore, the expansion of the over-the-counter segment is expected to grow in the market.

Route of Administration Insights

Topical administration dominated the market with the largest revenue share of 60.0% in 2024. This can be attributed to the growth of user-friendly delivery systems and effective treatments. Topical treatments allow for direct application to the affected area, enabling targeted therapies such as acne, psoriasis, and eczema, which enhances treatment effectiveness. In addition, the development of user-friendly systems, such as gels, creams, and patches, is also contributing to the growth in the market.

Parenteral administration is expected to grow with the fastest CAGR of 11.1% over the forecast period. This can be attributed to the growth for faster absorption of medications, which provides relief for patients with skin conditions; in addition, parenteral drugs bypass the digestive system, which avoids issues such as first-pass metabolism that can reduce the drug effectiveness when taken orally. Furthermore, this is also beneficial for patients who have difficulty swallowing pills, further driving the growth of parenteral routes in dermatological drugs.

Drug Class Insights

Corticosteroids dominated the market with the largest revenue share of 30.1% in 2024. This can be attributed to rising skin infection cases and the growth of research and development. Skin conditions such as eczema, psoriasis, and dermatitis are increasing, leading to great demand for effective treatments. Furthermore, advancements in research and development have resulted in new formulations and delivery methods for corticosteroids, which improve effectiveness and safety. Therefore, the growing recognition of this segment as an essential treatment for inflammatory skin conditions has driven the market.

Calcineurin inhibitors are expected to grow at the fastest CAGR of 11.1% over the forecast period. Effective treatments such as topical calcineurin inhibitors, including tacrolimus and pimecrolimus, are commonly used to treat eczema. They are also primarily used to treat vitiligo, psoriasis, and seborrheic dermatitis. They are beneficial for sensitive skin areas and prevent skin thinning, making them suitable for long-term management. Furthermore, the effectiveness and safety of calcineurin inhibitors are positioned to further grow in the market.

Distribution Channel Insights

Retail pharmacies dominated the market, with the largest revenue share of 50.6% in 2024. This can be attributed to OTC dermatological product growth and awareness of skin conditions. Skin conditions, such as acne and eczema, are leading patients to seek treatment, resulting in higher sales of dermatological products at retail pharmacies. Furthermore, the growing availability of OTC dermatological products is making it easier for consumers to access treatments without needing a prescription, further increasing sales. The rise in consumer awareness about skin health and the importance of skincare encourages people to purchase dermatological products.

Hospital pharmacies are expected to grow with a significant CAGR of 10.1% over the forecast period, attributed to a wide range of medications and demand for prescription-based dermatological treatments. The availability of a wide range of medications in hospital pharmacies allows healthcare professionals to recommend appropriate treatments, catering to patient needs. The presence of skilled healthcare providers in hospitals also enhances the likelihood of patients receiving the right prescriptions. Furthermore, the growing preference for purchasing medications from nearby pharmacies, combined with the availability of cost-effective OTC products, contributes to the expansion of this market.

Regional Insights

The dermatological drugs market in North America dominated the market with the largest revenue share of 38.6% in 2024, which can be attributed to advancements in drug development and increasing awareness. The growing incidence of skin conditions such as acne, psoriasis, and eczema is increasing the demand for effective treatments. For instance, a survey updated by CeraVe in September 2024 stated that over 80% of adults in the U.S. experience skin concerns, and only half of them visit a dermatologist annually. The survey highlights barriers to dermatological care, such as long wait times and lack of insurance, which prevent many from seeking specialized treatment. Moreover, advancements in drug development, such as biologics and targeted therapies, are enhancing the treatment options available to patients. Furthermore, the rise in OTC products is contributing to the market growth in North America.

U.S. Dermatological Drugs Market Trends

The U.S. dermatological drugs market dominated North America with the largest revenue share in 2024, attributed to the rising cases of skin infections and the growing pipeline of clinical studies. Skin conditions, particularly acne, have intensified the need for effective treatments. Topical retinoids and antibiotics such as doxycycline and minocycline are gaining popularity for their effectiveness and favorable safety profiles. Furthermore, clinical studies aim to develop new dermatological treatments that indicate a robust research environment.

Asia Pacific Dermatological Drugs Market Trends

Asia Pacific is expected to grow at the fastest CAGR of 11.7% over the forecast period. This can be attributed to the increasing awareness of skin conditions and improved healthcare infrastructure. The awareness of skin health and available therapies are shifting the focus of patients to seeking medical care and treatments such as topical retinoids, corticosteroids, and isotretinoin. In addition, the healthcare infrastructure, including molecular diagnostics and imaging technologies, is improving the accuracy and early diagnosis of skin conditions, which supports the development and availability of new dermatological drugs.

China Dermatological Drugs Market Trends

China dermatological drugs market dominated Asia Pacific with the largest revenue share in 2024, which can be attributed to the increasing purchase of skincare products and improved accessibility across urban and rural areas. The rise in disposable income among consumers also contributes to the growth, as individuals are invested in purchasing skincare products and medications. According to an article published by BusinessWire in September 2024, LEO Pharma submitted a New Drug Application (NDA) for Enstilar, a treatment for adults with plaque psoriasis, to the National Medical Products Administration in China. Furthermore, the NDA submission is backed by positive results in which the treatment is considered effective, further increasing growth in dermatological drugs.

Europe Dermatological Drugs Market Trends

Europe dermatological drugs market is expected to grow significantly over the forecast period, driven by the rising cases of skin diseases and preference for non-invasive treatments. Skin conditions such as acne, psoriasis, and eczema are becoming common due to factors such as pollution and dietary changes. According to an article published by EurekAlert in May 2022, dermatologists in Germany identified a link between acne and low levels of omega-3 fatty acids at the European Academy of Dermatology and Venereology Spring Symposium. The study involves 100 patients with acne, and 94.0% were found to have omega-3 levels below the recommended range, implying diet is expected to influence acne severity. Moreover, the rising awareness of skin care health is prompting patients to seek non-invasive treatments, resulting in the usage of dermatological drugs.

Key Dermatological Drugs Company Insights

Some key players in the market are AbbVie Inc., Pfizer Inc., and GSK plc.; Sun Pharmaceutical Industries Ltd.; GALDERMA; Amgen Inc.; Johnson & Johnson Services, Inc.; Novartis AG; Eli Lilly and Company; Almirall, S.A; and Bausch Health Companies Inc. These companies employ various strategies to gain a competitive edge, such as launching new products to cater to diverse patient needs, focusing on personalized medicine to enhance treatment efficacy, and leveraging emerging markets to tap into increasing awareness about dermatological drugs. Furthermore, these businesses engage in collaborative research initiatives with healthcare organizations to drive innovation while integrating digital health solutions for enhanced patient access and adherence.

• AbbVie Inc. is a biopharmaceutical company with a strong focus on dermatology, offering innovative treatments for various skin conditions. Its dermatological portfolio includes medications for chronic diseases such as psoriasis, atopic dermatitis, and hidradenitis suppurativa, with products such as RINVOQ demonstrating significant efficacy in clinical trials.

• Pfizer Inc. offers a range of dermatological treatments to address various skin conditions. Its product, CIBINQO, is an oral medication approved for moderate to severe atopic dermatitis, providing an effective option for patients who have not found relief with other treatments. In addition, the company offers EUCRISA, a non-steroidal topical ointment approved for treating mild to moderate eczema for patients aged two and older.

Recent Developments

• In August 2024, Sun Pharmaceutical Industries Ltd. launched STARIZO, an antibacterial treatment to combat Acute Bacterial Skin and Skin Structure Infections caused by drug-resistant bacteria such as MRSA in India. The medication offers the convenience of once-a-day dosing for six days, making it easier for patients than traditional treatments requiring more frequent dosing over longer periods.

• In January 2024, Pfizer Inc. partnered with Glenmark Pharmaceuticals to introduce abrocitinib, also known as CIBINQO, an oral treatment for atopic dermatitis in India. This treatment provides rapid itch relief and sustained disease control for patients suffering from this chronic skin condition.

Dermatological Drugs Market Report Scope

Global Dermatological Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the global dermatological drugs market report based on therapy, type, route of administration, drug class, distribution channel, and region.

• Therapy Outlook (Revenue, USD Million, 2018 - 2030)

  • Acne

  • Psoriasis

  • Rosacea

  • Alopecia

  • Others

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Prescription

  • Over-the-counter (OTC)

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Topical Administration

  • Oral Administration

  • Parenteral Administration

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Corticosteroids

  • Retinoids

  • Antibiotics

  • Antifungals

  • Calcineurin Inhibitors

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait